about
Outpatient Provider Contact Prior to Unintentional Opioid Overdose Among VHA Service Users.Prescription Opioid Use among Adults with Mental Health Disorders in the United States.Recent cannabis use among Veterans in the United States: Results from a national sample.Understanding Risk Factors for Opioid Overdose in Clinical Populations to Inform Treatment and Policy.Impact of the Opioid Safety Initiative on opioid-related prescribing in veterans.Use of non-pharmacological strategies for pain relief in addiction treatment patients with chronic pain.Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample.Opioid Overdose: Risk Assessment and Mitigation in Outpatient TreatmentClinical characteristics influencing age at onset in psychotic disorders.Discrepancies Between Perceived Benefit of Opioids and Self-Reported Patient Outcomes.Comparing antipsychotic treatments for schizophrenia: a health state approach.Pain acceptance and opiate use disorders in addiction treatment patients with comorbid pain.Perceptions and practices addressing diversion among US buprenorphine prescribers.Opioid Overdose-the Surgeon's Role.Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialtiesTelemedicine-delivered treatment interventions for substance use disorders: A systematic reviewBenzodiazepine Use and Misuse Among Adults in the United StatesCounty and Physician Variation in Benzodiazepine Prescribing to Medicare Beneficiaries by Primary Care Physicians in the USAChanging Trends in Opioid Overdose Deaths and Prescription Opioid Receipt Among VeteransPolysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration
P50
Q36240547-3CA0D9C6-FAE9-4C84-B94E-F785F9F7FB1AQ38399786-B7A7B6AE-F023-44A2-B7C9-0D8970E9C421Q38599985-66420E98-830C-434A-9C97-B81929C4CBC7Q38804957-CEB8E1BA-E77D-4C83-95AB-4709F368AF20Q38939771-96D5AD4A-2F53-47B7-A95B-3EE435B4CBCAQ39151518-A515E1CE-C548-4DA7-8CEA-D514F2D7CD5EQ39709131-72C5E6C7-F2E7-45CF-A22E-CBEE2C743D44Q42721546-B9CA5BD4-58BD-4A20-9EB5-7E13ABEBE9B3Q46212286-591BB20A-8C59-4521-B89B-E3073530DC55Q48003398-D3B9CB0A-465D-4419-BA3D-23DE92B2AB44Q48063467-7D4AB7FA-F191-460E-9BA6-2F2C8B197C30Q50963127-0D738516-6F4B-4D97-811F-5C5131397E09Q52316798-A1CDED47-9424-4E37-AF05-F844C865D97AQ52692787-A5948120-21BA-469A-A430-140200AC46F4Q60697167-6059A55E-A921-4DB5-B0CC-5FCDCAD98837Q90047593-A6B5C8DD-A6EE-4270-82C7-B506B400E862Q90565653-69092058-E50B-4AB2-8AA1-E6A1E00CA544Q91713306-02A7530A-D245-4028-97BE-F7A316AE8AF5Q92293359-91015B23-6527-43BD-B5E5-E031F60098FAQ95309255-D4FAB892-CD50-42EB-B6A8-43E7EF50B59D
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lewei Allison Lin
@ast
Lewei Allison Lin
@en
Lewei Allison Lin
@es
Lewei Allison Lin
@nl
Lewei Allison Lin
@sl
type
label
Lewei Allison Lin
@ast
Lewei Allison Lin
@en
Lewei Allison Lin
@es
Lewei Allison Lin
@nl
Lewei Allison Lin
@sl
prefLabel
Lewei Allison Lin
@ast
Lewei Allison Lin
@en
Lewei Allison Lin
@es
Lewei Allison Lin
@nl
Lewei Allison Lin
@sl
P106
P31
P496
0000-0003-2765-7814